Skip to content

Clinical study on the improvement of stable coronary heart disease patients' cardiopulmonary function and life quality score by Wenyang-Huoxue Prescription combined with Baduanjin and cardiac rehabilitation

Clinical study on the improvement of stable coronary heart disease patients' cardiopulmonary function and life quality score by Wenyang-Huoxue Prescription combined with Baduanjin and cardiac rehabilitation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062318
Enrollment
Unknown
Registered
2022-08-01
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Group A:Wenyang-huoxue & routine cardiac rehabilitation group
Group A:Baduanjin + routine cardiac rehabilitation group
Group C:Wenyang Huoxue& Baduanjin + routine cardiac rehabilitation group
Group D:routine cardiac rehabilitation group

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of stable angina pectoris of coronary heart disease; 2. Ages 35 to 79; 3. Meet the Canadian Society of Cardiology (CCS) Angina classification i-III; 4. The researcher judged it to be Yang deficiency and blood stasis syndrome; 5. Cooperate with follow-up; 6. Obtain informed consent and take the test voluntarily according to GCP regulations.

Exclusion criteria

Exclusion criteria: 1. Known left main coronary artery stenosis; 2. Systolic blood pressure >=160mmHg and/or diastolic blood pressure >=100 mmHg after uncontrolled hypertension or controlled by antihypertensive drugs; 3. Uncontrolled tachyarrhythmias that cause symptoms or hemodynamic disturbances; 4. High or complete mode conduction block; 5. Acute endocarditis; 6. Obstructive hypertrophic cardiomyopathy; 7. Symptomatic severe aortic stenosis, decompensated heart failure, acute pulmonary embolism, deep vein thrombosis, acute pericarditis or myocarditis, and acute aortic dissection; Chronic lung disease with symptoms of dyspnea; 9. Recent stroke or transient ischemic attack, with cognitive impairment; 10. Uncorrected clinical problems, such as infection, severe anemia, electrolyte disturbances, hyperthyroidism, etc; 11. Abnormal liver and kidney function (alanine aminotransferase or creatinine & GT; 2x upper limit of normal reference value); 12. Those who are unable to exercise due to physical disorders or other reasons; 13. People who have the habit of exercise (fixed exercise time & GT; 30min/ day or 3h/ week); 14. Attended other clinical investigators within the last 1 month; 15. There are other conditions that researchers consider inappropriate for study participation.

Design outcomes

Primary

MeasureTime frame
Peak VO2;

Secondary

MeasureTime frame
Aerobic threshold;VO2;VO2/HR;MVV;Maximum motion load;EqCO2;RER;

Countries

China

Contacts

Public ContactHu Xiaozhen

Shanghai Municipal Hospital of Traditional Chinese Medicine affiliated to Shanghai University of Traditional Chinese Medicine

274425809@qq.com+86 13774243895

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026